These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 21845053)

  • 1. Prolonged-release melatonin for insomnia - an open-label long-term study of efficacy, safety, and withdrawal.
    Lemoine P; Garfinkel D; Laudon M; Nir T; Zisapel N
    Ther Clin Risk Manag; 2011; 7():301-11. PubMed ID: 21845053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolonged release melatonin in the treatment of primary insomnia: evaluation of the age cut-off for short- and long-term response.
    Wade AG; Crawford G; Ford I; McConnachie A; Nir T; Laudon M; Zisapel N
    Curr Med Res Opin; 2011 Jan; 27(1):87-98. PubMed ID: 21091391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety.
    Wade AG; Ford I; Crawford G; McConnachie A; Nir T; Laudon M; Zisapel N
    BMC Med; 2010 Aug; 8():51. PubMed ID: 20712869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of prolonged-release melatonin for insomnia in middle-aged and elderly patients with hypertension: a combined analysis of controlled clinical trials.
    Lemoine P; Wade AG; Katz A; Nir T; Zisapel N
    Integr Blood Press Control; 2012; 5():9-17. PubMed ID: 22346363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lasting treatment effects in a postmarketing surveillance study of prolonged-release melatonin.
    Hajak G; Lemme K; Zisapel N
    Int Clin Psychopharmacol; 2015 Jan; 30(1):36-42. PubMed ID: 25054634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of 6-month nightly ramelteon administration in adults with chronic primary insomnia.
    Mayer G; Wang-Weigand S; Roth-Schechter B; Lehmann R; Staner C; Partinen M
    Sleep; 2009 Mar; 32(3):351-60. PubMed ID: 19294955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolonged release melatonin for improving sleep in totally blind subjects: a pilot placebo-controlled multicenter trial.
    Roth T; Nir T; Zisapel N
    Nat Sci Sleep; 2015; 7():13-23. PubMed ID: 25678831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of prolonged-release melatonin on sleep measures and psychomotor performance in elderly patients with insomnia.
    Luthringer R; Muzet M; Zisapel N; Staner L
    Int Clin Psychopharmacol; 2009 Sep; 24(5):239-49. PubMed ID: 19584739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of esmirtazapine in adult outpatients with chronic primary insomnia: a randomized, double-blind placebo-controlled study and open-label extension.
    Ivgy-May N; Hajak G; van Osta G; Braat S; Chang Q; Roth T
    J Clin Sleep Med; 2020 Sep; 16(9):1455-1467. PubMed ID: 32351205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case series of perimenopausal women with insomnia treated with mirtazapine followed by prolonged-release melatonin add-on and monotherapy.
    Dolev Z
    Arch Womens Ment Health; 2011 Jun; 14(3):269-73. PubMed ID: 21311927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Efficacy and Safety of Pediatric Prolonged-Release Melatonin for Insomnia in Children with Autism Spectrum Disorder.
    Maras A; Schroder CM; Malow BA; Findling RL; Breddy J; Nir T; Shahmoon S; Zisapel N; Gringras P
    J Child Adolesc Psychopharmacol; 2018 Dec; 28(10):699-710. PubMed ID: 30132686
    [No Abstract]   [Full Text] [Related]  

  • 12. Prolonged-release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects.
    Lemoine P; Nir T; Laudon M; Zisapel N
    J Sleep Res; 2007 Dec; 16(4):372-80. PubMed ID: 18036082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sleep, Growth, and Puberty After 2 Years of Prolonged-Release Melatonin in Children With Autism Spectrum Disorder.
    Malow BA; Findling RL; Schroder CM; Maras A; Breddy J; Nir T; Zisapel N; Gringras P
    J Am Acad Child Adolesc Psychiatry; 2021 Feb; 60(2):252-261.e3. PubMed ID: 31982581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study.
    Raghu G; van den Blink B; Hamblin MJ; Brown AW; Golden JA; Ho LA; Wijsenbeek MS; Vasakova M; Pesci A; Antin-Ozerkis DE; Meyer KC; Kreuter M; Moran D; Santin-Janin H; Aubin F; Mulder GJ; Gupta R; Richeldi L
    Lancet Respir Med; 2019 Aug; 7(8):657-664. PubMed ID: 31122893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of prolonged release melatonin in insomnia patients aged 55-80 years: quality of sleep and next-day alertness outcomes.
    Wade AG; Ford I; Crawford G; McMahon AD; Nir T; Laudon M; Zisapel N
    Curr Med Res Opin; 2007 Oct; 23(10):2597-605. PubMed ID: 17875243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing the potential for drug interactions and long term safety of melatonin for the treatment of insomnia in children with autism spectrum disorder.
    Zisapel N
    Expert Rev Clin Pharmacol; 2022 Feb; 15(2):175-185. PubMed ID: 35285365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of prolonged-release melatonin in insomnia patients with diabetes: a randomized, double-blind, crossover study.
    Garfinkel D; Zorin M; Wainstein J; Matas Z; Laudon M; Zisapel N
    Diabetes Metab Syndr Obes; 2011; 4():307-13. PubMed ID: 21887103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 12-week, randomized, double-blind, placebo-controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia.
    Ancoli-Israel S; Krystal AD; McCall WV; Schaefer K; Wilson A; Claus R; Rubens R; Roth T
    Sleep; 2010 Feb; 33(2):225-34. PubMed ID: 20175406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term efficacy and safety of zolpidem extended-release 12.5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: a 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study.
    Krystal AD; Erman M; Zammit GK; Soubrane C; Roth T;
    Sleep; 2008 Jan; 31(1):79-90. PubMed ID: 18220081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Melatonin: Physiological and pharmacological aspects related to sleep: The interest of a prolonged-release formulation (Circadin
    Quera-Salva MA; Claustrat B
    Encephale; 2018 Dec; 44(6):548-557. PubMed ID: 30107892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.